Global Liver Institute
News
GLOBAL LIVER INSTITUTE
Advancements in the Liver Cancer Landscape
Welcome back to Liver Cancers News – where we keep you up-to-date on what’s happening in the liver cancer world.
Addressing Unmet Needs in Peds and Rare Liver Diseases
Concerted efforts are driving positive change in the pediatric and rare liver disease community! Read on for details:
GLI Supports NIH Naming Dr. Marrazzo as New Director of the National Institute of Allergy and Infectious Diseases
Global Liver Institute supports the selection of Jeanne M. Marrazzo, M.D., as director of the National Institute of Allergy and Infectious Diseases (NIAID) by the acting director of the NIH. Dr. Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham and is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America.
Technology at Work
Read along for some updates about cutting-edge technology in rare liver disease that should improve prompt diagnosis, ongoing feedback, and effective interventions.
GLI Leads Charge for Common-Sense Policies to Advance High Quality Care for Everyone
In July, GLI used its voice to challenge policymakers to take steps to advance high quality, equitable care for everyone.
Striving For a Better Future in Cancer
Welcome back to Liver Cancers News – where we keep you up-to-date on what’s happening in the liver cancer world.
GLI and Others Nominate Julius M. Wilder MD, PhD to National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC)
Global Liver Institute is pleased to nominate Julius M. Wilder MD, PhD to be a member of the NIDDK’s National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC).
GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)
Global Liver Institute recognizes the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH affects more than 148 million people and continues to become more prevalent each year.
Charting the Course of NASH
The 6th International NASH Day was a resounding global success, with over 100 partners from 55 countries participating.
Noteworthy Progress in Patient Advocacy & Clinical Trials
Actively supporting advocacy efforts and engaging in novel clinical trials can provide patients with a sense of hope for potential therapies and assurance in the management of their condition.
Discoveries in HCC and Biliary Tract Cancer
It’s not only important to GLI to keep you updated; we value your input and updates.
GLI Leads Bipartisan Access to Innovation Strategy Across HHS, Congress, and the White House
We have so much more to do to support liver health and appreciate your consistent engagement and support in those efforts!